Skip to main content
. Author manuscript; available in PMC: 2021 Feb 12.
Published in final edited form as: J Alzheimers Dis. 2020;78(3):989–1010. doi: 10.3233/JAD-200896

Table 3A.

Consequences a 12-month treatment with benfotiamine. A. Benfotiamine did not cause any adverse events

Symptom Placebo (n = 36) Treatment (n = 34)
Anxiety 4 (11%) 5 (14%)
Bruise 5 (14%) 2 (6%)
Cold symptoms 3 (8%) 3 (8%)
Depression 2 (6%) 1 (3%)
Dizziness 3 (8%) 3 (8%)
Fall 12 (34%) 6 (17%)
Head injury 2 (6%) 0 (0%)
Heart arrhythmia 2 (6%) 1 (3%)
Pain 4 (11%) 5 (14%)
Pneumonia 3 (8%) 0 (0%)
Sprain 2 (6%) 0 (0%)
Surgery 3 (8%) 1 (3%)
Allergy 2 (2%) 0 (0%)
Gastrointestinal problem 12 (34%) 9 (26%)
Stroke 0 (0%) 2 (6%)
Total 59 38